Zollinger’s ulcer (Gastric ulcer) - Symptoms, Causes, Treatment & Prevention

Overview

Zollinger’s ulcer is a specific type of gastric (stomach) ulcer that occurs in patients with a rare neuroendocrine tumor called a Zollinger–Ellison syndrome (ZES) gastrinoma. The tumor secretes excessive amounts of gastric acid, overwhelming the protective mucus lining of the stomach and duodenum and producing deep, often refractory ulcers.

Although gastric ulcers are common (affecting up to 10% of the adult population at some point in life¹), Zollinger’s ulcers are uncommon because the underlying gastrinoma occurs in roughly 1–3 per million people each year². They can affect both men and women, typically between the ages of 30–60, but can appear at any age.

Symptoms

Because the ulcers are driven by massive acid output, symptoms may be more severe or persistent than those of “ordinary” peptic ulcers.

• Epigastric pain – burning or gnawing pain 1–3 hours after meals or when the stomach is empty. Pain may improve briefly with antacids but returns.
• Heartburn / acid reflux – frequent sour taste, especially at night.
• Frequent nausea or vomiting – may contain undigested food or, in severe cases, blood.
• Weight loss – due to pain‑related avoidance of food.
• Diarrhea or steatorrhea – excess acid inactivates pancreatic enzymes, leading to malabsorption.
• Gastro‑intestinal bleeding – melena (black tarry stools) or hematemesis (vomiting blood).
• Upper abdominal fullness or bloating.
• Fatigue and anemia – from chronic blood loss.
• Refractory ulcer disease – ulcers that do not heal after several weeks of standard therapy.

Causes and Risk Factors

Primary cause

Zollinger’s ulcer is secondary to a gastrinoma—most often located in the “gastrinoma triangle” (pancreas head, duodenum, and the common bile duct). The tumor autonomously secretes gastrin, a hormone that stimulates parietal cells to produce hydrochloric acid. Acid levels can exceed 10‑30 mmol/L (normal < 4 mmol/L) leading to mucosal damage.

Risk factors for developing a gastrinoma

• Multiple Endocrine Neoplasia type 1 (MEN 1) – Genetic syndrome (mutations in the MEN1 gene) present in 20–30 % of gastrinomas.
• Family history of MEN 1 or sporadic gastrinoma.
• Age 30‑60 – Peak incidence.
• Male sex – Slightly higher prevalence, though overall difference is modest.
• Smoking – May increase gastrin secretion and ulcer risk.
• Helicobacter pylori infection – While not a direct cause of gastrinoma, it can exacerbate ulcer formation and mask the diagnosis.

Diagnosis

Diagnosis involves confirming the presence of a gastrinoma, demonstrating hypergastrinemia, and localizing the tumor.

Laboratory tests

• Fasting serum gastrin – Levels > 1000 pg/mL are highly suggestive of ZES; values 200‑1000 pg/mL require provocative testing.
• Secretin stimulation test – In ZES, gastrin paradoxically rises > 120 pg/mL after IV secretin; a key diagnostic maneuver (sensitivity ≈ 94%).
• pH measurement – Basal gastric pH < 2 confirms acid hypersecretion.
• Complete blood count – May reveal iron‑deficiency anemia.

Imaging for tumor localization

• Endoscopic ultrasound (EUS) – Highly sensitive for lesions ≤ 1 cm in pancreas/duodenum.
• Multiphasic contrast CT or MRI – Detects larger lesions and assesses liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan®) or Ga‑68 DOTATATE PET/CT – Gold standard for detecting small or metastatic neuroendocrine tumors.
• Upper endoscopy (EGD) – Visualizes ulcer(s) and obtains biopsies to rule out malignancy.

Biopsy

Routine ulcer biopsies are performed to exclude gastric cancer, especially in patients over 55 or with atypical ulcer appearance.

Treatment Options

Management aims to (1) control acid hypersecretion, (2) eradicate or control the gastrinoma, and (3) heal existing ulcers.

Acid‑suppression therapy

• High‑dose Proton Pump Inhibitors (PPIs) – Omeprazole 40‑80 mg daily (or equivalent) is first‑line; many patients require lifelong dosing.
• Potassium‑competitive acid blockers (P‑CABs) – Vonoprazan (approved in Asia, under U.S. review) offers rapid, potent acid control.
• H2‑receptor antagonists – Used as adjuncts when PPIs are insufficient.

Control of the gastrinoma

• Surgical resection – Preferred for localized tumors (< 2 cm) without metastasis; can be curative in 60‑80 % of sporadic cases.
• Somatostatin analogs (octreotide, lanreotide) – Inhibit gastrin release; useful for unresectable or metastatic disease.
• Targeted therapy – Everolimus or sunitinib for progressive neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor positive metastases.
• Chemotherapy – Rarely needed; reserved for high‑grade neuroendocrine carcinomas.

Lifestyle and supportive measures

• Avoid tobacco, alcohol, and NSAIDs (including aspirin).
• Eat small, non‑spicy meals; avoid lying down within 2 hours of eating.
• Maintain adequate calcium and vitamin D intake; monitor bone density (chronic PPI use can affect calcium absorption).
• Screen for and treat Helicobacter pylori infection if present.

Living with Zollinger’s Ulcer (Gastric Ulcer)

Medication adherence

Because acid hypersecretion is usually lifelong, taking PPIs exactly as prescribed is critical. Use a medication diary or smartphone reminder.

Monitoring

• Annual endoscopy to verify ulcer healing and rule out malignancy.
• Periodic fasting gastrin and gastric pH assessments to gauge disease control.
• Imaging (CT/MRI) every 6‑12 months if tumor is known to be metastatic.

Nutrition

Focus on a balanced diet rich in lean protein, whole grains, and low‑fat dairy. Consider a dietitian’s help if malabsorption causes weight loss.

Psychosocial support

Living with a rare chronic disease can be stressful. Support groups (e.g., NET Patient Foundation) and counseling improve quality of life.

Prevention

While you cannot prevent a genetic gastrinoma, you can reduce ulcer‑related complications:

• Quit smoking and limit alcohol intake.
• Use NSAIDs only under physician guidance; consider COX‑2 selective agents if needed.
• Screen for H. pylori and eradicate it if positive.
• Maintain a healthy weight to lower baseline gastric acid output.
• Adhere to routine follow‑up appointments.

Complications

If untreated or inadequately controlled, Zollinger’s ulcers can lead to:

• Bleeding – Acute hemorrhage requiring transfusion or endoscopic hemostasis.
• Perforation – Emergency surgery needed; mortality up to 20 % in elderly patients.
• Gastric outlet obstruction – Chronic scarring leads to vomiting and malnutrition.
• Penetration into adjacent organs – E.g., pancreas, liver.
• Malignancy – Gastrinomas are malignant in 60‑90 % of cases; metastatic spread to liver or lymph nodes is common.
• Bone demineralization – Chronic PPI use plus acid excess can impair calcium absorption.

When to Seek Emergency Care

References

1. Mayo Clinic. “Peptic ulcer.” Updated 2023. https://www.mayoclinic.org
2. American Cancer Society. “Gastrinoma (Zollinger‑Ellison syndrome).” 2022. https://www.cancer.org
3. National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison Syndrome.” 2021. https://www.niddk.nih.gov
4. WHO. “Neuroendocrine Tumours.” 2020. https://www.who.int
5. Cleveland Clinic. “Management of Gastric Ulcers and ZES.” 2023. https://my.clevelandclinic.org
6. J. Falch, et al. “Guidelines for the diagnosis and management of Zollinger‑Ellison syndrome.” *Gastroenterology* 2022;162:1234‑1245.